Siebel, Thomas M, CEO of C3.ai, sells $7.6m in stock
John Turman Fleming, a director at USANA Health Sciences Inc . (NYSE:USNA), recently sold 500 shares of the company’s common stock. According to InvestingPro analysis, USANA demonstrates strong financial fundamentals with an impressive gross profit margin of 80.5% and maintains more cash than debt on its balance sheet. The shares were sold at an average price of $29.6589 per share, totaling approximately $14,829. Following this transaction, Fleming holds 4,200 shares directly. This sale was reported in a filing with the Securities and Exchange Commission for the period ending June 9, 2025. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, one of 1,400+ detailed company analyses available to subscribers.
In other recent news, USANA Health Sciences reported its Q1 2025 earnings, revealing a mixed financial performance. The company posted earnings per share (EPS) of 0.73, which fell short of the forecasted 0.8. However, USANA’s revenue reached $250 million, surpassing expectations of $243.15 million, driven by strong sales growth in Mainland China. Notably, net sales in China surged by 64%, contributing significantly to the company’s overall 12% year-over-year increase in consolidated net sales. The first full quarter following the Hyatt acquisition also bolstered USANA’s competitive position. Despite the EPS miss, the revenue beat reflects continued investor optimism, as evidenced by the subsequent rise in USANA’s stock. The company plans to focus on expanding its children’s health and wellness offerings with new product launches in the latter half of 2025. Analyst firm Sidoti and Company noted the positive momentum in China and South Korea, while Tigress Financial Partners highlighted the successful integration of the Hyatt acquisition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.